AbbVie Inc. $ABBV Shares Sold by Harvest Portfolios Group Inc.

Harvest Portfolios Group Inc. trimmed its position in AbbVie Inc. (NYSE:ABBV) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 278,996 shares of the company’s stock after selling 6,573 shares during the period. AbbVie comprises about 1.1% of Harvest Portfolios Group Inc.’s portfolio, making the stock its 26th largest holding. Harvest Portfolios Group Inc.’s holdings in AbbVie were worth $63,748,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Chelsea Counsel Co. acquired a new stake in AbbVie in the 3rd quarter worth about $26,000. Westend Capital Management LLC acquired a new stake in AbbVie during the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter worth $31,000. Legacy Wealth Managment LLC ID grew its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC grew its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. UBS Group dropped their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a report on Thursday, April 30th. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Trading Up 2.1%

NYSE ABBV opened at $213.77 on Wednesday. The stock has a fifty day simple moving average of $209.49 and a 200-day simple moving average of $219.84. The stock has a market cap of $377.69 billion, a PE ratio of 105.31, a P/E/G ratio of 0.72 and a beta of 0.32. AbbVie Inc. has a twelve month low of $180.25 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the previous year, the firm earned $2.46 EPS. The business’s revenue was up 12.4% on a year-over-year basis. Research analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is presently 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s neuroscience drugs boosted Q1 sales growth, with neuroscience revenue rising 26% year over year thanks to Vraylar, migraine treatments and Botox, signaling continued strength in a key growth area. Here’s How Neuroscience Drugs Boost AbbVie’s Q1 Sales Growth
• Positive Sentiment: AbbVie was highlighted in valuation-focused articles as potentially undervalued, which can support the stock by drawing attention to its earnings and dividend appeal. 3 Stocks That May Be Priced Below Their Estimated Value In May 2026
• Neutral Sentiment: AbbVie was listed among trending stocks after increased user interest on Zacks, but the coverage did not point to a new material catalyst by itself. Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
• Neutral Sentiment: Evercore ISI slightly lowered its price target on AbbVie to $235 from $236, which is a small adjustment and not a major negative signal for the stock. AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI
• Negative Sentiment: Broader pharmaceutical-policy headlines about Trump’s drug-pricing push could weigh on the sector, since lower Medicare pricing would pressure pharma margins and sentiment. Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.